Amoxil recall hits GSK Pakistan revenue in otherwise strong year

Deregulated drug pricing allowed the company to improve gross margins, but the recall still caused revenue to decline

GlaxoSmithKline Pakistan Ltd (PSX: GLAXO) has just delivered one of those “two-truths” sets of numbers that investors in Pakistan’s pharmaceutical sector are rapidly getting used to: a sharp improvement in profitability metrics, alongside signs that demand is not keeping pace with the industry’s new pricing reality.

On the surface, the year looks like a breakout. Chase Securities’ briefing note highlights earnings per share (EPS) of Rs20.52 for CY24, compared to Rs1.68 in CY23 – a leap that speaks to both the operating leverage in the business and the impact of the industry’s shift in pricing power. The same note points to a still-resilient performance in the latest reported quarter: 3QCY25 EPS of Rs6.40, up from Rs6.05 a year earlier.

But revenue is telling a more complicated story – particularly in the most recent period. The company’s net sales in 3QCY25 are shown at Rs14.2 billion, down 4% year-on-year. In the same quarter, gross profit rose 29% and gross margin widened dramatically to 37% (from 27%), aided by a 16% decline in cost of sales. Put differently: pricing and product mix are now doing the heavy lifting, even when volumes and revenue wobble.

Management’s explanation for the weaker revenue trend converges on two intertwined issues.

 

To read the full article, subscribe and support independent business journalism in Pakistan

The content in this publication is expensive to produce. But unlike other journalistic outfits, business publications have to cover the very organizations that directly give them advertisements. Hence, this large source of revenue, which is the lifeblood of other media houses, is severely compromised on account of Profit’s no-compromise policy when it comes to our reporting. No wonder, Profit has lost multiple ad deals, worth tens of millions of rupees, due to stories that held big businesses to account.

Hence, for our work to continue unfettered, it must be supported by discerning readers who know the value of quality business journalism, not just for the economy but for the society as a whole.

(Already a subscriber? Click here to login)
  • Full Price Subscription Plans

    Not only will you be supporting independent journalism, 25% of the amount from your subscription will be used to subsidise those subscribers who cannot afford the full price of the subscription. As a subscriber you will get full access to exclusive paywalled content, and an ad free reading experience. Yearly full price subscription plans also include a complimentary annual subscription to The Wall Street Journal.

    +

  • Subsidised Subscription Plans

    Pay part of the full subscription price, if you cannot afford to pay all of it, and the rest will be subsidised by a full paying subscriber. As a subscriber you will get access to exclusive paywalled content, and an ad free reading experience.

  • Free Student Subscriptions

    If you are currently a student, you can claim an already-paid-for digital subscription, courtesy

    As a subscriber you will get access to exclusive paywalled content, an ad free reading experience.

     

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular Posts